Rodent neuroprotection models
- Reported quantity
- 1–10 mg/kg of the HNG analogue intraperitoneally
- Frequency
- Daily or every other day
- Study duration
- 1–4 weeks
Native humanin requires substantially higher quantities than HNG for the same readout.
Protocols · Longevity
Humanin: literature-reported ranges
Humanin was identified in a screen of surviving neurons in Alzheimer's brain tissue and is studied for cytoprotection, insulin sensitivity and neuronal survival. Nearly all quantitative work uses the potentiated analogue HNG rather than native humanin.
Read this first
Every figure on this page is a range reported in published literature or in a publicly documented study protocol. It is a record of what researchers used, not a recommendation, a therapeutic protocol, or advice. Peptide Intel Hub is an independent publication, sells nothing, and describes these compounds as in-vitro research reagents only.
Compound at a glance
- Class
- 24-amino-acid mitochondrial-derived peptide
- Reported half-life
- Short for the native peptide; analogues such as HNG are engineered for longer exposure
- Routes used in the literature
- Intraperitoneal, intracerebroventricular and subcutaneous in animal models
- Also written as
- —
What the published studies reported
Each row below describes one body of work. The model and population are part of the figure — a rodent per-kilogram quantity and a human trial quantity are not comparable.
In-vitro cytoprotection assays
- Reported quantity
- 1 nM to 10 µM
- Frequency
- Single exposure
- Study duration
- 24–72 hours
HNG is reported as roughly 1000-fold more potent than native humanin in these assays.
Reconstitution maths
A 10 mg vial in 2 mL of bacteriostatic water gives 5 mg/mL. Confirm whether the vial contains native humanin or the HNG analogue — they are not interchangeable.
Open the reconstitution calculatorHow to read these figures
- Native versus HNG analogue is the most important label detail for this compound.
- Much of the published work uses central rather than peripheral administration.
- Human circulating levels have been measured observationally, but no dosing trial exists.
Sources and citations
These are the published records the figures on this page are drawn from. Each one describes what researchers administered, in which model or population, and over what period. Quantities reported in a study are specific to that study's design and are not transferable guidance.
- [1]Humanin Prevents Age-Related Cognitive Decline in Mice and is Associated with Improved Cognitive Age in Humans
Yen K, Wan J, Mehta HH, et al. · Scientific Reports · 2018 · PMID 30242290
Aged mice received chronic administration of the humanin analog HNG via osmotic minipump to assess prevention of age-related cognitive decline.
View the record - [2]Chronic treatment with the mitochondrial peptide humanin prevents age-related myocardial fibrosis in mice
Qin Q, Mehta HH, Yen K, et al. · American Journal of Physiology-Heart and Circulatory Physiology · 2018 · PMID 30004252
Aged mice were chronically treated with a humanin analog to evaluate prevention of age-related myocardial fibrosis.
View the record - [3]Acute humanin therapy attenuates myocardial ischemia and reperfusion injury in mice
Muzumdar RH, Huffman DM, Atzmon G, et al. · Arteriosclerosis, Thrombosis, and Vascular Biology · 2010 · PMID 20651283
Mice subjected to myocardial ischemia-reperfusion were given acute intraperitoneal humanin treatment to assess cardioprotective effects.
View the record
Search the databases yourself
Read the Humanin research briefOther longevity compounds
CartalaxSynthetic tripeptide (Ala-Glu-Asp) bioregulatorEpithalonSynthetic tetrapeptide (Ala-Glu-Asp-Gly)FOXO4-DRIFOXO4-p53 interaction-disrupting retro-inverso peptideGlutathioneEndogenous tripeptide antioxidant (Glu-Cys-Gly)
All research protocolsPeptide Intel Hub is an independent publication and has no affiliation, ownership or commercial relationship with the suppliers listed. We sell nothing and take no payments — links are editorial references only.